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Neurocognitive deficits are a core feature of schizophrenia and, therefore, represent potentially critical outcome variables for assessing
antipsychotic treatment response. We performed genome-wide association studies (GWAS) with 492K single nucleotide
polymorphisms (SNPs) in a sample of 738 patients with schizophrenia from the Clinical Antipsychotic Trials of Intervention Effectiveness
study. Outcome variables consisted of a neurocognitive battery administered at multiple time points over an 18-month period, measuring
processing speed, verbal memory, vigilance, reasoning, and working memory domains. Genetic mediation of improvements in each of
these five domains plus a composite neurocognitive measure was assessed for each of five antipsychotics (olanzapine, perphenazine,
quetiapine, risperidone, and ziprasidone). Six SNPs achieved genome-wide significance using a pre-specified threshold that ensures, on
average, only 1 in 10 findings is a false discovery. These six SNPs were located within, or in close proximity to, genes EHF, SLC26A9,
DRD2, GPR137B, CHST8, and IL1A. The more robust findings, that is those significant across multiple neurocognitive domains and having
adjacent SNPs showing evidence for association, were rs286913 at the EHF gene (p-value 6.99 108, q-value 0.034, mediating the
effects of ziprasidone on vigilance), rs11240594 at SLC26A9 (p-value 1.4 107, q-value 0.068, mediating the effects of olanzapine on
processing speed), and rs11677416 at IL1A (p-value 6.67 107, q-value 0.081, mediating the effects of olanzapine on working memory).
This study has generated several novel candidate genes for antipsychotic response. However, our findings will require replication and
functional validation. To facilitate replication efforts, we provide all GWAS p-values for download.
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Schizophrenia is an often devastating neuropsychiatric
illness. Biological factors have been strongly implicated
and considerable efforts are currently being devoted to
finding genes that increase susceptibility to the disease. One
eventual goal of these efforts is the identification of novel
drug targets to develop better therapeutic compounds
(Sanger, 2004; Williams, 2003). However, the development
of new drugs is extremely expensive and takes many years
(Roses, 2000). Arguably, a more immediate role for genetic
markers in the treatment and management of schizophrenia
is to improve our ability to tailor the prescription of exis-
ting drugs to individual patients (Malhotra et al, 2004).
Typically, only a proportion of patients respond to any
given antipsychotic drug (Kane, 1999). The several weeks it
may take clinicians to declare a treatment ineffective leaves
the patient vulnerable to continuing dysfunction and
suicide (Meltzer and Okayli, 1995). The clinical benefits of
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a genetic test to identify the most effective antipsychotic
treatment for each patient at time of first presentation
would be considerable (Basile et al, 2002).
Despite some encouraging signs, efforts to predict
antipsychotic treatment response have met with limited
success (Malhotra et al, 2004). One of the complications is
that neuropsychiatric clinical phenotypes are complex and
heterogeneous and, therefore, may not be optimal measures
in pharmacogenomic studies. An alternative is to focus on
the amelioration of specific deficits related to the disorder.
Patients with schizophrenia show deficits across a large
number of neurocognitive domains and these deficits are
regarded as the single strongest correlate of real world
functioning (Green, 1996). Although there is variability
among patients (Kremen et al, 2004), neurocognitive
deficits are present by the first episode and persist through-
out the course of the illness (Mesholam-Gately et al, 2009).
Substantial evidence points to neurocognitive deficits in the
relatives of schizophrenic probands (Hill et al, 2008) and a
large consortium study found moderate, but significant,
heritabilities for all neurocognitive measures investigated,
with estimates ranging from 24 to 55% (Greenwood et al,
2007). The motivational and cognitive impairments of
schizophrenia are strongly associated with the long-term
disability typically produced by the disease, and this is
why cognitive deficits are increasingly being seen as targets
for treatment (Hyman and Fenton, 2003). Crucially, for
our purposes, previous studies have shown improvement
in neurocognitive function following treatment with
several different antipsychotic drugs (Keefe et al, 2007a, b).
Taken together, these observations suggest that neuro-
cognitive deficits represent potentially critical outcome
variables for the pharmacogenomic study of antipsychotic
drug response.
To date, pharmacogenomics studies have typically focused
on candidate genes, selected for encoding of drug targets
(pharmacodynamic candidates) or for involvement in the
metabolism of the drug itself (pharmacokinetic candidates).
Pharmacodynamic candidates in schizophrenia include
dopamine or serotonin receptors and several studies have
shown positive associations between, for example, dopamine
receptors D2 (DRD2) and D3 (DRD3) and antipsychotic
response (see Arranz and de Leon, 2007, for a review).
Pharmacokinetic candidates, particularly the cytochrome
P450 genes, are well known to harbor genetic variation
affecting the metabolism of antipsychotics (Kirchheiner et al,
2004). Nevertheless, a limitation of prior studies in this area
is that the selection of candidate genes is restricted to current
knowledge about mechanisms of drug action. More explora-
tory methods that systematically screen the whole genome
for association with drug response likely represent a superior
strategy for discovering relevant genetic variation. Such
genome-wide association studies (GWAS) have become
feasible in recent years and have already shown considerable
promise to identify novel associations between genetic
variants and complex traits (Altshuler et al, 2008). Indeed,
several large-scale GWAS for schizophrenia have been
recently published. Associations have been found with, for
example, the MHC region (Shi et al, 2009) and novel loci
such as ZNF804A (O’Donovan et al, 2008). To date, though,
the number of GWAS on antipsychotic response is
considerably more modest (Zandi and Judy, 2010).
In this study, we use the Clinical Antipsychotic Trials of
Intervention Effectiveness (CATIE) study (Lieberman et al,
2005; Stroup et al, 2003) to detect genetic variation
underlying changes in neurocognitive functioning following
treatment with five different antipsychotics. The sample
consisted of 738 CATIE subjects with DSM-IV schizophre-
nia diagnoses who were genotyped using the Affymetrix
500K platform plus a custom 164K chip to improve genome-
wide coverage (Sullivan et al, 2008). Treatment outcome
was measured using a comprehensive neurocognitive
assessment battery in five domains: processing speed,
verbal memory, vigilance, reasoning, and working memory,
in addition to a composite measure that condensed




A total of 765 subjects from the CATIE study gave informed
consent to participate in genetic studies. The patients were
diagnosed with schizophrenia using the Structured Clinical
Interview for DSM-IV (First et al, 1994). This sample has
been carefully described elsewhere (Lieberman et al,
2005; Stroup et al, 2003). In short, CATIE is a multiphase
randomized controlled trial of antipsychotic medications,
including the second-generation drugs, olanzapine, quetia-
pine, risperidone, and ziprasidone, compared with a mid-
potency first-generation drug, perphenazine. Patients were
followed for up to 18 months and, to maximize representa-
tiveness, the participants were recruited from 57 clinical
settings around the United States. The mean age for the
participants was 40.9 years and on average they first
received antipsychotic medication 14.3 years previously. All
participants or their legal guardians gave written informed
consent and the institutional review board at each site
approved the study.
Neurocognitive Assessment Battery
For CATIE, a neurocognitive advisory group was convened
and arrived at consensus regarding the contents, standardi-
zation, and methodology of the neurocognitive assessment
battery (Keefe et al, 2003, 2006). Eleven tests were
administered, resulting in 24 individual scores. Factor
analysis showed that a model comprised of five domain
scores provided the best fit (Keefe et al, 2006). The five
neurocognitive domains were processing speed that is based
on the standardized mean of grooved pegboard (Lafayette
Instrument Company, 1989), WAIS-R digit symbol test
(Wechsler, 1981), and the mean of the two verbal fluency
measures (Benton, 1978); verbal memory was assessed with
the Hopkins verbal learning test (average of three trials)
(Brandt, 1991); vigilance was based on the continuous
performance test d-prime scores (average of 2-digit, 3-digit,
and 4-digit) (Cornblatt et al, 1988); reasoning summary
score was the mean of Wisconsin card sorting test (Heaton
et al, 1993) and WISC-R mazes (Wechsler, 1991); working
memory summary score was the average of a computerized
test of visuospatial working memory (sign reversed)
(Lyons-Warren et al, 2004) and letter number sequencing
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(Gold et al, 1997). The correlations among the five domain
scores were medium to high and we, therefore, also analyze
the standardized composite score of these five domains
(Keefe et al, 2006).
Estimating Treatment Effects
Multiple assessments were available per patient (Table 1).
There was a mean of 3.4 assessments per subject.
Conventional approaches to calculating treatment effects
(eg, post-treatmentFpre-treatment difference scores)
define treatment using only two observations. Alternatively,
using all available assessments can substantially improve
statistical power to detect true associations. For this reason,
we have developed a systematic method (van den Oord et al,
2009) using mixed effects modeling (Goldstein, 1995; Searle
et al, 1992) to estimate treatment effects. We first determine
the functional form of the drug response trajectory, then
screen many possible covariates to select those that improve
the precision of the treatment effect estimates, and finally
generate individual drug effect estimates based on the
best fitting model using best linear unbiased predictors
(Pinheiro and Bates, 2000) (see Supplementary Material for
details). Intuitively, these treatment effects quantify how
much each subject’s phenotype changes in response to a
given drug, relative to the average effect for all subjects who
took the drug. Each treatment effect measure was screened
for outliers using the multivariate outlier method developed
by Hadi (Hadi and Simonoff, 1993). This procedure
quantifies the (Mahalanobis) distance of each observation
from the centroid of all observations. We excluded
observations that were outlying at po0.05. The majority
of distributions showed 0 outliers and none exhibited 42
(7 total outliers out of 30 outcome distributions). After
excluding outliers, outcomes were all virtually perfectly
normally distributed: mean skewness¼0.025 or 0.209
when taking the mean of the absolute values, while mean
kurtosis¼ 0.534 (signed) or 0.585 (absolute).
Genotyping and Genotype Quality Control
DNA sampling, GWAS genotyping, and genotype quality
control (QC) have been described previously for this sample
(Sullivan et al, 2008). Briefly, a total of 665 439 single
nucleotide polymorphisms (SNPs) were genotyped for each
subject using both the Affymetrix 500K ‘A’ chipset (Santa
Clara, CA, USA) and a custom 164K SNP-chip created by
Perlegen (Mountain View, CA, USA). Highly stringent QC
protocols were implemented. Of the 500 568 SNPs on the
Affymetrix arrays, 79.8% passed initial QC, while 66.1%
of the 164 871 SNPs on the custom Perlegen chip passed
initial QC. Additional SNPs with allele frequencies o0.01
and those with 2 disagreements among 36 pairs of replicate
samples were removed. Subjects with sex discrepancies,
cryptic duplicates, and those with excessive missing
genotypes were removed (see Supplementary Materials).
After QC, a total of 492 900 SNP genotypes from 738
individuals remained for analysis.
Ancestral Background
Approximately 57% of the CATIE subjects self-identify
themselves as white/European American (EA) and 29% as
black/African American (AA). The remaining 14% of the
patients consider themselves to have ‘other’ ancestral
origins or to belong to multiple ancestral categories. To
avoid false positives due to population stratification,
Sullivan et al (2008) previously performed an extensive
evaluation of multiple methods to control for ancestral
heterogeneity in CATIE. They concluded that the principal
component and multi-dimensional scaling (MDS) approach
worked best. We, therefore, proceeded with the MDS
approach as implemented in PLINK (Purcell et al, 2007).
For our analyses, we used five MDS dimensions that
appeared to capture the majority of ancestry-related effects
in CATIE (see Supplementary Materials for details).
Association Testing and False Discovery Rate Control
All association testing was conducted in PLINK (Purcell
et al, 2007) using a linear regression model with the five
population stratification MDS dimensions as covariates. We
used a false discovery rate (FDR) (Benjamini and Hochberg,
1995)-based approach to declare significance. In comparison
with controlling a family-wise error rate (eg, Bonferroni’s
correction), the FDR (a) provides a better balance between
finding true effects vs controlling false discoveries,
(b) results in comparable standards for declaring signifi-
cance across studies because it does not directly depend on
the number of tests, and (c) is relatively robust against
having correlated tests (Brown and Russell, 1997). The FDR
is commonly used in many high-dimensional applications
and has also successfully been applied in the context of
GWAS (Beecham et al, 2009; Lei et al, 2009; Liu et al, 2009).
As motivated previously, we chose an FDR threshold of 0.1
for declaring genome-wide significance (van den Oord and
Sullivan, 2003). This means that on average 10% of the SNPs
declared significant are expected to be false discoveries.
Table 1 Number of Subjects/Assessments Analyzed for Each Antipsychotic and Neurocognitive Outcome
Olanzapine Perphenazine Quetiapine Risperidone Ziprasidone
Verbal memory 223/459 109/223 198/325 213/413 138/254
Vigilance 215/430 102/203 190/305 202/381 133/234
Processing speed 223/459 109/223 198/325 213/413 138/254
Reasoning 223/459 109/223 198/325 213/413 138/254
Working memory 223/459 108/222 198/325 213/413 138/254
Neurocognitive composite 223/459 109/223 198/325 213/413 138/254
The slightly smaller numbers in vigilance are attributable to invalid scores from computerized testing (see Keefe et al, 2006).
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Operationally (Black, 2004), the FDR was controlled using
q-values that are FDRs calculated using the p-value of the
markers as thresholds for declaring significance (Storey,
2003; Storey and Tibshirani, 2003). It is important to note
that performing many GWAS analyses does not present a
problem for the FDR because it controls the expected ratio
of false to all discoveries. Thus, when many GWAS are
performed, the number of false positives will increase and
so will the number of true positives. The expected ratio of
false to all discoveries will, therefore, remain 0.1 with our
threshold for declaring genome-wide significance regardless
of how many GWAS are performed.
To avoid an all-or-nothing conclusion about whether an
SNP is significant and improve the interpretation of our
GWAS results, we also estimated for each SNP the local FDR
(lFDR) (Efron et al, 2001) using a precise method specifically
designed for GWAS studies (Bukszar et al, 2009). This
estimated lFDR is the posterior probability that the SNP has
no effect. In addition to reporting p- and q-values, we also
report the effect size for our top findings, that is increase in
explained variance (r2) for each of the genome-wide significant
SNPs when the SNP in question is added to the regression
model (without the MDS dimensions).
Candidate Gene Analysis
To select candidate genes for drug effects, we selected all
genes that had previously shown positive associations with
response to any antipsychotic drug using any outcome
measure, as reviewed by Arranz and de Leon (2007), plus
additional genes with reported positive associations since
publication of that article (Anttila et al, 2007; Campbell
et al, 2008; Hamdani et al, 2008; Hwang et al, 2007;
Mancama et al, 2007; Meary et al, 2008). We also included
all genes involved in the major and secondary metabolic
pathways of antipsychotic drugs (Arranz and de Leon,
2007). Finally, we also included two genes (RIMS1 and
GRM8) that showed promising associations in a recent
candidate gene study of antipsychotic response in CATIE
(Need et al, 2009), using a different analytical approach to
that presented here. This gave a total of 41 candidate genes.
SNPs were selected in these genes using a liberal definition
of the gene boundary (±B50 kb), to avoid excluding SNPs
in the region that may be in linkage disequilibrium (LD)
with others within the gene itself, or that may be in
proximal regions of regulatory importance. In total, we
identified 1595 SNPs corresponding to the 41 candidate
genesFB39 SNPs per gene (see Supplementary Table S4;
Supplementary Material).
RESULTS
When generating the outcome measures, two were found to
show limited individual differences in treatment response,
that is variance was close to zero. These were perphenazine
with vigilance and perphenazine with working memory.
GWAS were not performed for these outcomes because any
findings would not be associated with individual differences
in treatment, but simply sampling error. Quantile–Quantile
(QQ) plots and Manhattan plots for each of the remaining
successful GWAS are available in the online Supplementary
Material. All p-values for each GWAS are available for
download at http://www.people.vcu.edu/~jlmcclay. Table 2
shows the number of significant GWAS results at various
FDR thresholds. For concision, Table 2 presents significant
results grouped by outcome or by drug. Six SNPs exceeded
our pre-specified genome-wide significance threshold,
which controls the FDR at the 0.1 level (van den Oord
and Sullivan, 2003). When grouped by medication, the
largest numbers of genome-wide significant results were
found for olanzapine (m¼ 5); when grouped by neurocog-
nitive outcome, the largest number of findings were found
for working memory (m¼ 4). Figure 1 shows the regional
plots of the genome-wide significant findings, while Figure 2
shows the outcome scores by genotype.
Table 3 provides details on those SNPs that were either
genome-wide significant (q-value o0.1) or ‘potentially
interesting’ at a q-value threshold o0.25. The most
significant SNP overall, rs286913, reached genome-
wide significance (p-value¼ 6.99 108, q-value¼ 0.034,
r2¼ 0.213) and appeared to mediate the effects of ziprasi-
done on vigilance. This SNP lies within an intron of the EHF
(ETS homologous factor) gene that is located on chromo-
some 11p12. An additional SNP in EHF, rs286928, also
mediated the effects of ziprasidone on vigilance and was
located some 16 kb from rs286913. LD between these two
markers was high, with r2¼ 0.87 in EAs and 0.46 in AAs. A
regional plot of p-values for all CATIE SNPs at this locus
(Figure 1) shows their position relative to the gene.
Haplotype analysis of these two SNPs plus an additional
six flanking markers yielded several highly significant
findings in the EA subsample (the largest single ethnic
group in CATIE). However, the best p-value among the
haplotypes tested (p¼ 1.18 105) was only marginally
more significant than the single marker p-value for rs286913
in EA (p¼ 1.8  105), suggesting that this marker alone is
Table 2 Number of GWAS q-values Below Various Thresholds
q-value threshold
0.1 0.25 0.5 0.75 0.95
By neurocognitive scale
Neurocognitive composite 0 0 3 78 160
Working memory 4 12 43 95 162
Reasoning 0 10 27 49 171
Processing speed 1 1 8 61 97
Verbal memory 0 0 2 29 126
Vigilance 1 2 4 8 97
Total 6 25 87 320 813
By drug
Olanzapine 5 10 23 32 141
Quetiapine 0 11 48 206 286
Risperidone 0 2 9 31 184
Ziprasidone 1 2 5 29 141
Perphenazine 0 0 2 22 61
Total 6 25 87 320 813
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probably sufficient to capture the association. In addition
to mediating the effects of ziprasidone on vigilance,
rs286913 showed association (po0.05) for additional drug
and outcome combinations. These included ziprasidone
with the neurocognitive composite measure (p¼ 0.0082),
risperidone and reasoning (p¼ 0.0015), and risperidone
with working memory (p¼ 0.035). The p-values for all six
genome-wide significant SNPs across all 28 drug/outcome
combinations are shown in Supplementary Tables S4A and
B in the Supplementary Material.
Figure 1 (a and b) Regional plots of p-values for SNPs flanking the six genome-wide significant findings (solid black dots). The y axis is the –log10 of the
p-values for each SNP, while the x axis denotes genomic position according to genome build 36 (hg18). All genotyped SNPs within B±100 kb of
























































































Figure 2 Box and whisker plots of treatment response, by genotype, for the six genome-wide significant SNP associations. The y axis units are SD.
Vigil_zipras¼ vigilance with ziprasidone; Speed_olanza¼ processing speed with olanzapine; Memory_olanza¼working memory with olanzapine. For
rs4805924 and rs11214606, only two genotpype groups are plotted. Although rare allele homozygotes were present for both SNPs in CATIE, none of
these had at least two observations in the relevant neurocognitive outcome/drug combination (working memory and olanzapine) to allow a treatment effect
to be calculated.
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The second most significant locus was rs11240594 on
chromosome 1q32 that appeared to mediate the effects of
olanzapine on processing speed (p-value¼ 1.4 107,
q-value¼ 0.068, r2¼ 0.125). The SNP is located in an intron
of SLC26A9 (solute carrier family 26 (sulfate transporter),
member 9). Multiple neighboring SNPs in LD with rs11240594
also appeared to tag the same signal (see Figure 1). These
included rs12727528 (p-value¼ 5.65 105 in EA) and several
other markers with p-values B 103. In addition to mediating
the effects of olanzapine on processing speed, rs11240594
showed association (po0.05) with olanzapine and verbal
memory (p¼ 0.0377), vigilance (p¼ 0.0434), and the neuro-
cognitive composite (p¼ 0.0022), in addition to ziprasidone
with processing speed (p¼ 0.0012).
Among the six genome-wide significant results was
rs11214606 at DRD2 that mediated the effect of olanzapine
on working memory (p-value 4.84 107, q-value 0.081,
r2¼ 0.120). As DRD2 is a well-known candidate for anti-
psychotic response and a drug target of all antipsychotic
medications, this was an encouraging finding. Nevertheless,
as can be seen in Figure 1, rs11214606 is an orphan finding,
with no other SNPs in the region showing substantial
evidence for association. Consistent with HapMap data,
however, LD between rs11214606 and neighboring markers
is very low, that is r2 does not exceed 0.05 in the CATIE
sample. Therefore, we cannot expect neighboring markers
to tag the same signal. SNP rs11214606 did not show
association at the po0.05 level with any other drug
or outcome combination, although there were trends
approaching significance with other outcomes related
to olanzapine (see Supplementary Material).
All of the remaining SNPs achieving genome-
wide significance were also with olanzapine and
working memory. These included rs7520258 (p-value
5.1 107, q-value 0.081, r2¼ 0.120), located in an intron
of the GPR137B (G protein-coupled receptor 137B) gene on
chromosome 1q42–43 and rs4805924 (p-value 6.1 107,
q-value 0.08, r2¼ 0.119), which is situated B7 kb from the
start of transcription at CHST8 (carbohydrate (N-acetylga-
lactosamine 4-0) sulfotransferase 8) on chromosome 19q13.
(However, the more recent genome build 37.1 provisionally
locates rs4805924 in an intron of CHST8). As can be seen
Table 3 Summary of top findings with q-values below 0.25.
Outcome Locus Test
Drug Measure SNP ID Gene Chr Posn (bp) MAF N p-val q-val lFDR Eff
Ziprasidone Vigilance rs286913 EHF 11 34 611 939 0.051 127 6.99E-08 0.034 0.241 +
Ziprasidone Vigilance rs286928 EHF 11 34 596 076 0.044 126 6.06E-07 0.147 0.689 +
Olanzapine Processing speed rs11240594 SLC26A9 1 204 162 858 0.191 213 1.40E-07 0.068 0.390 +
Olanzapine Working memory rs11214606 DRD2 11 112 815 079 0.034 203 4.84E-07 0.081 0.442 
Olanzapine Working memory rs7520258 GPR137B 1 234 379 750 0.066 203 5.10E-07 0.081 0.453 
Olanzapine Working memory rs4805924 CHST8 19 38 860 113 0.024 202 6.17E-07 0.081 0.493 
Olanzapine Working memory rs11677416 IL1A 2 113 245 711 0.253 200 6.67E-07 0.081 0.509 +
Olanzapine Working memory rs17561 IL1A 2 113 253 694 0.253 203 1.05E-06 0.102 0.604 +
Quetiapine Working memory rs11110077 ANKS1B 12 98 790 244 0.109 176 3.70E-07 0.129 0.448 
Quetiapine Working memory rs12726652 1 107 234 099 0.264 177 5.31E-07 0.129 0.522 
Quetiapine Working memory rs6856328 LPHN3 4 62 119 913 0.074 178 8.26E-07 0.133 0.612 
Quetiapine Working memory rs7770731 6 14 706 799 0.292 182 1.23E-06 0.149 0.690 +
Quetiapine Reasoning rs4611189 11 40 794 289 0.034 186 6.16E-07 0.161 0.584 
Quetiapine Reasoning rs17126180 ANKRD33 12 50 550 223 0.059 189 9.13E-07 0.161 0.658 +
Quetiapine Reasoning rs17108533 MAP3K9 14 70 319 555 0.102 188 9.96E-07 0.161 0.674 +
Quetiapine Working memory rs16865258 CLDN1 3 191 480 090 0.015 182 1.74E-06 0.169 0.750 
Olanzapine Reasoning rs2833556 HUNK 21 32 207 171 0.314 212 4.59E-07 0.188 0.633 +
Olanzapine Reasoning rs2286720 LYZL4 3 42 423 475 0.073 215 1.00E-06 0.188 0.760 
Olanzapine Reasoning rs17706989 WWOX 16 77 127 458 0.031 214 1.16E-06 0.188 0.781 
Quetiapine Reasoning rs1264202 ZNF706 8 102 297 099 0.313 189 1.72E-06 0.209 0.764 
Quetiapine Working memory rs4293296 CDKN3 14 53 927 036 0.291 181 2.94E-06 0.237 0.825 
Olanzapine Working memory rs6707600 ITSN2 2 24 375 270 0.019 203 2.97E-06 0.240 0.792 
Risperidone Reasoning rs3753242 PRKCZ 1 1 548 310 0.057 199 9.71E-07 0.243 0.794 +
Risperidone Reasoning rs17689437 ZFP90 16 67 157 852 0.131 204 1.00E-06 0.243 0.797 +
Quetiapine Reasoning rs6436839 PID1 2 229 678 042 0.289 183 2.58E-06 0.249 0.820 
Summary of top findings with q-values below 0.25. Where more than one marker at a locus has findings qo0.25, these have been grouped and shaded in grayscale.
Genomic position is indicated according to genome build 36 (hg18). MAF is the minor allele frequency and lFDR is the local false discovery rate, which provides
a marker-specific estimate of the posterior probability that the finding is false positive. ‘Eff’ is the direction of effect of the minor allele, eg, ‘ + ‘ indicates a greater
improvement in neurocognitive function for the minor allele compared with the major allele.
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from the regional plots in Figure 1, both of these findings
are isolated with no neighboring SNPs showing robust
evidence for association. In particular, it is worth remarking
that rs7520258 at GPR137B is almost invariant in EAs (MAF
o 0.01 in CATIE), suggesting that the signal, if true, is
almost entirely coming from the non-EA ethnic groups. For
the finding at CHST8, HapMap shows rs4805924 to be in an
LD block of 22 kb. However, within this block only two
HapMap SNPs were in high LD with rs4805924 (rs16968363
and rs10500266, both with r2¼ 0.79) and these were not
genotyped in CATIE. Of the remaining SNPs in the block
that were genotyped in our sample, none showed LD
with r240.15 and, therefore, could not be expected to tag
the same signal. Nevertheless, despite a lack of suitable
SNP proxies, both of these genome-wide significant SNPs
showed some evidence for association (po0.05) across
different neurocognitive domains and drugs. In addition to
the primary finding with olanzapine and working memory,
rs7520258 appeared to mediate the effects of ziprasidone
on processing speed (p¼ 0.0133), while rs4805924
showed association with olanzapine and processing speed
(p¼ 0.0045), in addition to olanzapine and the neurocog-
nitive composite (p¼ 0.0029).
The final genome-wide significant finding, again with
olanzapine and working memory, is rs11677416 (p-value
6.67  107, q-value 0.081, r2¼ 0.119), located B2 kb from
the boundary of IL1A (interleukin-1-a) on chromosome
2q14. This SNP showed evidence for association across
other neurocognitive domains, including olanzapine with
reasoning (p¼ 0.0045), vigilance (p¼ 0.0084), and the
neurocognitive composite (p¼ 0.0003), in addition to
perphenazine and reasoning (p¼ 0.0065). Another SNP,
rs17561, B8 kb from rs11677416, was almost genome-wide
significant with a q-value of 0.102. This latter SNP is located
in the coding sequence of IL1A and gives rise to a non-
synonymous amino-acid substitution of alanine to serine at
protein position 114. Consistent with HapMap data, the two
SNPs were in almost perfect LD in our sample (r2¼ 0.97 in
AA and 0.99 in EA), suggesting that both markers are
tagging the same signal.
Candidate Gene Analysis
In addition to the GWAS results, we also report our findings
for markers located in, or in the vicinity of, specific
candidate genes. Examination of 1595 SNPs at 41 candidate
genes, that is B39 SNPs per gene (see Supplementary Table
S5; Supplementary Material, p15) yielded only three
findings with q-values below 0.5. The remaining tests all
had q-values very close to 1. This was somewhat surprising,
because far fewer tests are performed relative to GWAS
and FDR-based q-values are known to be too liberal in
these scenarios (Zaykin et al, 2000). However, the lack of
complete coverage for many important candidate genes
using these arrays, as we have discussed before (McClay
et al, 2009), means that we cannot reliably exclude
association for many of these loci. The top finding in this
analysis was rs11214606 at DRD2, mediating the effects
of olanzapine on working memory (p-value¼ 4.84 107,
q-value¼ 0.022). This is the same SNP at DRD2 that
was genome-wide significant in the main analysis. The
remaining findings with ‘potentially interesting’ q-values
were rs7766029 at cannabinoid receptor 1 (CNR1),
mediating the effects of perphenazine on verbal memory
(p-value¼ 1.76 105, q-value¼ 0.391) and rs936465 at
DRD4 that mediated the effects of ziprasidone on the
neurocognitive composite measure (p-value¼ 3.13  105,
q-value¼ 0.463).
DISCUSSION
Understanding the genetic variation affecting response to
antipsychotic drugs is important to develop novel diag-
nostic tests to match individual patients with schizophrenia
to the most effective and safe medication. In this study, we
performed GWAS of antipsychotic response, using neuro-
cognitive function as the outcome variable(s). In addition
to being a core deficit in schizophrenia, neurocognitive
functions can be viewed as endophenotypes for the disorder
and as such provide outcome measures that are poten-
tially more genetically simple and tractable. In total, six
markers achieved genome-wide significance in our study.
In comparison with a previous study that we carried out in
CATIE that used schizophrenia symptoms on the positive
and negative syndrome scale (PANSS) as the outcome
variables, this study with neurocognitive phenotypes would
appear to be the more successful. Our study using the
PANSS found only a single SNP to be significant at
a genome-wide level and only three SNPs in genes with
q-values o 0.5 (McClay et al, 2009).
An SNP in DRD2 reached genome-wide significance,
mediating the effect of olanzapine on working memory.
DRD2 is a well-known candidate for antipsychotic response
and is a drug target of olanzapine (Kapur et al, 1999).
However, despite the strong theoretical rationale for this
gene being associated with antipsychotic drug response, our
association evidence for DRD2 is perhaps less robust than is
the case with some of the other genome-wide significant
findings. First, no neighboring SNPs in our sample showed
evidence for association, although LD between neighboring
markers was low. Furthermore, the SNP was not signifi-
cantly associated with other outcome variables in our study,
although there were trends toward significance with some
other olanzapine-related variables that were in the same
direction as the primary finding (eg, reasoning, neurocognitive
compositeFsee Supplementary Table S4A in the Supplemen-
tary Material). If the effect is real, it is likely quite small and,
therefore, difficult to detect consistently in samples of the
size used here. Even in view of DRD2’s status as a likely
antipsychotic pharmacogene, our finding at this locus should
still be viewed as preliminary and requiring replication.
Our top finding overall was an SNP in the EHF (ETS
homologous factor) gene on chromosome 11. This gene is a
member of the ETS family of transcription factors, which
are involved in many aspects of gene regulation and
development. EHF is expressed at high levels in epithelial
tissues, primarily in glandular epithelium such as prostate,
pancreas, salivary gland, and trachea (Kas et al, 2000). Out
of 438 EHF tissue-specific human cDNA clones in AceView
(Thierry-Mieg and Thierry-Mieg, 2006) (http://www.ncbi.
nlm.nih.gov/IEB/Research/Acembly/index.html), only a sin-
gle clone of EHF was found in brain. Thus, while expression
in brain cannot be completely ruled out, it is likely to be at
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very low levels. Current information on this gene and its
function is relatively sparse. One of the few specific known
actions of EHF is as a transcriptional repressor downstream
of mitogen-activated protein kinase (MAPK) signaling
cascades (Tugores et al, 2001). This is possibly of note
because mitogen-activated protein kinase kinase kinase 9
(MAP3K9), an epithelial-specific MAPK (Dorow et al, 1993),
also emerged as one of our most significant findings
(Table 3).
The second best genome-wide significant finding was
with SLC26A9 (solute carrier family 26, sulfate transporter,
member 9), which is a member of the SLC26 sulfate/anion
transporter gene family. These are anionic transporters
involved in chloride and bicarbonate ion absorption or
secretion in epithelia (Loriol et al, 2008). The product
of SLC26A9 is a highly selective chloride ion channel that
is regulated by WNK kinases (Dorwart et al, 2007). It is
expressed at high levels in airway and gastric surface
epithelia, but is also expressed in the brain (based on the
AceView (Thierry-Mieg and Thierry-Mieg, 2006) and
UniGene (Wheeler et al, 2003) databases). It is a relatively
uncharacterized gene, but its regulation by WNK kinases,
specifically WNK4, may be significant. WNK4 has been
shown to interact with intersectin (He et al, 2007) and
we found ITSN2 (intersectin 2) among our top findings
(q-value¼ 0.24). WNK4 is also known to regulate cellular
chloride ion permeability and is localized to tight junctions
(Kahle et al, 2004), that is networks of sealing strands that
join epithelial cell membranes, thereby creating a virtually
impermeable barrier to fluid. One of the two major classes
of tight junction proteins is the claudins, the other being the
occludens. We found CLDN1 (claudin 1) to be associated
with quetiapine and working memory with a q-value of
0.169. Claudins are well recognized to have a major function
in cellular permeability (Tsukita and Furuse, 2000).
These associations with EHF and other epithelial-related
genes would not appear to have such an obvious connection
to antipsychotics as compared, for example, with DRD2.
However, with the caveat that these findings still require
replication, a plausible hypothesis is that these genes are
involved in epithelial barrier permeability. The role of
epithelial barriers in pharmacokinetics has long been
established. As such, our GWAS may have simply
uncovered specific loci harboring variation that contribute
to individual differences in barrier permeability, and by
extension, antipsychotic availability and efficacy. As most
antipsychotics are administered orally, absorption across
gut epithelia is a plausible mechanism, as is elimination of
drug across hepatic or renal epithelia. Also, it is conceivable
that the closely related endothelial tissues of the blood–
brain barrier may be involved.
Two SNPs among our top hits were at interleukin-1-a
(IL1A), which also appeared to mediate the effect of
olanzapine on working memory. It has been shown that
intravenous administration of human interleukin-1-a
protein induces memory impairments in mice (Banks
et al, 2001). However, there does not appear to be any
existing evidence in the literature linking IL1A to anti-
psychotics or schizophrenia. Interleukin-1-b (IL1B), which
is located B45 kb from IL1A, has been previously
associated with altered brain structure in patients with
schizophrenia (Meisenzahl et al, 2001). However, the
association in this study is clearly localized to IL1A
(Figure 1) and as mentioned in Results, one of the two
top SNPs in IL1A (rs17561) is non-synonymous, leading to an
amino-acid change at protein position 114. This SNP, therefore,
makes an appealing target for future functional study.
We previously reported ANKS1B as one of our top
findings in a CATIE pharmacogenomics GWAS, mediating
the effects of olanzapine on negative symptoms (McClay
et al, 2009), as measured by the PANSS. In this study, we
again find ANKS1B among our top findings, this time
mediating the effect of quetiapine on working memory. As
these findings are both in the same sample, and negative
symptoms are known to be correlated with neurocognitive
functioning, the fact that we see the same gene appearing in
both analyses may not appear too surprising. However, in
CATIE, the subjects being treated with one drug are for an
important part different from those treated with a second
drug. For example, only 49 CATIE subjects received
both quetiapine and olanzapine. Furthermore, correlations
between drug effects on negative symptoms and cognitive
function (working memory in this specific instance) are
present, but not particularly large (typically in the 0.1–0.2
range). Thus, due to largely non-overlapping samples and
modest correlation between drug effects on negative
symptoms and cognitive function, the ANKS1B findings in
CATIE involve to a large extent independent observations.
Furthermore, it is of note that ANKS1B also appeared
among the top findings in a GWAS of citalopram response
carried out by another group in the sequenced treat-
ment alternatives to relieve depression (STAR*D) sample
(Garriock et al, 2010). While this gene remains to be fully
characterized, a recent study identified the ANKS1B protein
to be part of a large post-synaptic complex, containing
many neurotransmitter receptors and other proteins of
relevance to schizophrenia (Fernandez et al, 2009). Clearly,
the next step with ANKS1B, in addition to replication, is to
identify possible causative variants. In our GWAS, we
observed another ankyrin-related gene, ANKRD33 (ankyrin
repeat domain 33), among the top findings. While there is
currently little to no literature on this gene, its association
in our GWAS may suggest a more general role for ankyrin
proteins in antipsychotic response.
CHST8 (carbohydrate N-acetylgalactosamine 4-0 sulfo-
transferase 8) was also significant at the genome-wide level.
The function of its gene product is to carry out the sulfation
of carbohydrates. Little published material is available on
this gene, but it is considered a plausible pharmacokinetics
candidate gene. For example, markers at this locus are
included on the Affymetrix DMET plus array, which is
designed to detect variation relevant to drug metabolizing
enzymes and transporters (Burmester et al, 2010). The
remaining genes among our top findings (ie, q-value o
0.25) are either uncharacterized or have biological functions
that do not immediately suggest obvious links to anti-
psychotic efficacy. For example, GPR137B (G protein-
coupled receptor 137B), which achieved genome-wide
significance for mediating the effects of olanzapine on
working memory, is a member of the G protein-coupled
receptor superfamily and is known to be expressed in brain
(UniGene). However, its associated ligand has not yet been
discovered and no other information on the function of this
receptor is available currently.
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We present our results with some caveats and cautions.
First, it has been shown previously that practice/placebo
effects can be apparent with the types of neurocognitive
outcome described here (Goldberg et al, 2007; Keefe et al,
2008). It is possible that the significant findings reported
here reflect a genetically mediated ability to benefit from
practice or general placebo effects such as expectation bias.
Second, the reported effect sizes for the associated SNPs are
most certainly overestimates. That is, because of sampling
error, effect sizes in an initial study are often greater
than those reported in subsequent replications (Goring
et al, 2001; Ioannidis et al, 2001). Finally, chance findings
are a possibility, as with any association study. Even with
FDR control at the 0.1 level, 1 in 10 findings, on average, will
be a false positive. This issue can only be addressed through
replication in independent samples. To facilitate this, we
provide all p-values (http://www.people.vcu.edu/~jlmcclay)
for download as a resource for investigators with the
requisite samples to carry out replication. However, to some
extent, the GWAS would appear to have served its purpose,
in that it immediately suggests novel follow-up experiments,
in addition to simple replication.
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